Chronic Semaglutide Treatment in Rats Leads to Daily Excessive Concentration-Dependent Sucrose Intake

CONTEXT: The glucagon-like peptide-1 receptor (GLP-1R) agonist semaglutide (SEMA) produces 15% weight loss when chronically administered to humans with obesity. METHODS: In 2 separate experiments, rats received daily injections of either vehicle (VEH) or SEMA starting at 7 µg/kg body weight (BW) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Cawthon, Carolina R, Blonde, Ginger D, Nisi, A Valentina, Bloomston, Haley M, Krubitski, Belle, le Roux, Carel W, Spector, Alan C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10306276/
https://www.ncbi.nlm.nih.gov/pubmed/37388574
http://dx.doi.org/10.1210/jendso/bvad074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10306276/
https://www.ncbi.nlm.nih.gov/pubmed/37388574
http://dx.doi.org/10.1210/jendso/bvad074

Ejemplares similares